Skip to main content

Advertisement

Table 4 Summary of studies on prostate cancer treated with radiotherapy using hypofractionation

From: Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer

Author and publication, year Technique No. of patients Stage T1–2 (%) ADT (%) Median follow-up (months) Total dose (Gy) Dose per fraction (Gy) NTD2Gy (Gy2) 5-year bRFS rate (%) Rate of late GI events (%) Rate of late GU events (%)
Grade ≥ 2 Grade ≥ 3 Grade ≥ 2 Grade ≥ 3
Kupelian et al. [12], 2007 IMRT 770 95 60 45 70 2.5 80.0 83 4.5 1.4 5.3 0.1
Pollack et al. [13], 2013 IMRT 151 86 45 68.4 70.2 2.7 84.4 76.7 18.1 2 21.5 4
Arcangeli et al. [14], 2012 3D-CRT 83 65 100 70 62 3.1 81.5 85 17 1.2 16 1.2
Kuban et al. [15], 2010 IMRT 102 NR 21 55.2 72 2.4 80.2 96 11 3 19 0
Lukka et al. [28], 2005 3D-CRT 466 100 0 68.4 52.5 2.6 61.5 40 NR 1.3 NR 1.9
Yeoh et al. [29], 2011 2D, 3D-CRT 108 100 0 90 55 2.75 66.8 55.9 NR NR NR NR
Leborgne et al. [30], 2011 3D-CRT 114 95.6 NR 49 60
63
3 or 3.15 77.1 or 83.7 89 4.4 0.9 4.4 1.8
Norkus et al. [31], 2009 3D-CRT 47 98 0 12 57 3 (13 fraction) or 4.5 (4 fraction) 81.0 NA NR NR NR NR
Dearnaley et al. [32], 2016 IMRT 1074 91 97 62.4 60 3 77.1 90.6 11.9 < 1 11.7 < 1
1077 90 97 57 73.3 85.9 11.3 < 1 6.6 1
Incrocci et al. [33, 34], 2016 IMRT 407 48 66 60 64.6 3.4 90.4 80.5 21.9 3.3 41.3 19.0
Lee et al. [35], 2016 3D-CRT or IMRT 550 100 0 69.6 70 2.5 80.0 86.3 22.4 4.1 29.7 3.5
Present series IMRT 596 98 61 62 76.70 2.19 80.9 92.7 8.5 1.2 19.4 1.1
  1. bRFS biochemical relapse-free survival, ADT androgen deprivation therapy, NTD 2Gy normalized total doses in 2 Gy/fraction equivalents with an α/β ratio of 1.5 Gy, GI gastrointestinal, GU genitourinary, 3D-CRT 3-dimensional conformal radiotherapy, NR not reported, NA not analyzed, IMRT intensity-modulated radiotherapy, EQD 2 equivalent dose in 2 Gy/fraction